Market Closed -
Nasdaq
04:00:00 2024-05-15 pm EDT
|
5-day change
|
1st Jan Change
|
13.12
USD
|
-0.30%
|
|
+15.09%
|
+61.18%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
99.63
|
361.6
|
373.5
|
84.56
|
205.7
|
333
|
-
|
-
|
Enterprise Value (EV)
1 |
99.63
|
361.6
|
373.5
|
84.56
|
205.7
|
333
|
333
|
333
|
P/E ratio
|
-0.67
x
|
-4.84
x
|
-5
x
|
-1.06
x
|
-2.06
x
|
-3.35
x
|
-4.79
x
|
-9.15
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.71
x
|
4.09
x
|
182
x
|
32.6
x
|
-
|
1,665
x
|
11
x
|
3.62
x
|
EV / Revenue
|
5.71
x
|
4.09
x
|
182
x
|
32.6
x
|
-
|
1,665
x
|
11
x
|
3.62
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-0.86
x
|
-
|
-
|
-
|
-
|
-2.85
x
|
-3.27
x
|
-3.78
x
|
FCF Yield
|
-116%
|
-
|
-
|
-
|
-
|
-35.1%
|
-30.6%
|
-26.4%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
6,196
|
14,148
|
15,182
|
17,508
|
25,268
|
25,308
|
-
|
-
|
Reference price
2 |
16.08
|
25.56
|
24.60
|
4.830
|
8.140
|
13.16
|
13.16
|
13.16
|
Announcement Date
|
3/11/20
|
3/18/21
|
3/28/22
|
3/14/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
17.46
|
88.52
|
2.053
|
2.596
|
-
|
0.2
|
30.23
|
92.09
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-132.3
|
-49.36
|
-61.41
|
-72.94
|
-92.08
|
-115.5
|
-109.1
|
-75.12
|
Operating Margin
|
-758.14%
|
-55.76%
|
-2,991.18%
|
-2,809.59%
|
-
|
-57,741.43%
|
-360.82%
|
-81.57%
|
Earnings before Tax (EBT)
1 |
-149.2
|
-67.53
|
-71.2
|
-73.81
|
-87.37
|
-118.7
|
-109.6
|
-73.53
|
Net income
1 |
-149.2
|
-67.73
|
-71.2
|
-73.81
|
-87.37
|
-118.4
|
-109.6
|
-73.52
|
Net margin
|
-854.77%
|
-76.51%
|
-3,468.1%
|
-2,843.3%
|
-
|
-59,209.9%
|
-362.65%
|
-79.84%
|
EPS
2 |
-24.00
|
-5.280
|
-4.920
|
-4.560
|
-3.960
|
-3.924
|
-2.748
|
-1.438
|
Free Cash Flow
1 |
-115.6
|
-
|
-
|
-
|
-
|
-117
|
-102
|
-88
|
FCF margin
|
-662.13%
|
-
|
-
|
-
|
-
|
-58,500%
|
-337.37%
|
-95.56%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
3/18/21
|
3/28/22
|
3/14/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.545
|
2.596
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.0571
|
0.0571
|
0.1143
|
0.8
|
5.5
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-16.51
|
-16.98
|
-21.4
|
-17.71
|
-16.85
|
-19.34
|
-20.29
|
-21.31
|
-31.14
|
-28.06
|
-28.36
|
-29.3
|
-30.07
|
-30
|
-26
|
Operating Margin
|
-3,029.54%
|
-654.08%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-49,632.24%
|
-51,285.56%
|
-26,308.01%
|
-3,750%
|
-472.73%
|
Earnings before Tax (EBT)
1 |
-16.48
|
-16.96
|
-21.95
|
-18.09
|
-16.81
|
-15.71
|
-24.28
|
-20
|
-27.37
|
-33.86
|
-28.4
|
-29.56
|
-30.49
|
-31
|
-28
|
Net income
1 |
-16.48
|
-16.96
|
-21.95
|
-18.09
|
-16.81
|
-15.71
|
-24.28
|
-20
|
-27.37
|
-33.86
|
-28.4
|
-29.56
|
-30.49
|
-31
|
-28
|
Net margin
|
-3,024.04%
|
-653.39%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-49,707.3%
|
-51,729.09%
|
-26,678.62%
|
-3,875%
|
-509.09%
|
EPS
2 |
-1.200
|
-1.080
|
-1.440
|
-1.080
|
-0.9600
|
-0.9600
|
-1.370
|
-0.7500
|
-1.020
|
-1.260
|
-0.9960
|
-0.9840
|
-0.9160
|
-0.7900
|
-0.7100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/28/22
|
5/9/22
|
8/8/22
|
11/3/22
|
3/14/23
|
5/9/23
|
8/8/23
|
11/8/23
|
3/14/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-116
|
-
|
-
|
-
|
-
|
-117
|
-102
|
-88
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.01
|
0.03
|
0.2
|
-
|
-
|
0.25
|
0.13
|
0.13
|
Capex / Sales
|
0.04%
|
0.04%
|
9.55%
|
-
|
-
|
125%
|
0.41%
|
0.14%
|
Announcement Date
|
3/11/20
|
3/18/21
|
3/28/22
|
3/14/23
|
3/14/24
|
-
|
-
|
-
|
Last Close Price
13.16
USD Average target price
28.79
USD Spread / Average Target +118.74% Consensus |
1st Jan change
|
Capi.
|
---|
| +61.67% | 333M | | +5.33% | 111B | | +12.11% | 106B | | -12.56% | 22.24B | | -3.64% | 21.25B | | -5.94% | 18.97B | | -35.21% | 18.52B | | -10.86% | 16.81B | | +37.57% | 12.54B | | -26.24% | 8.09B |
Bio Therapeutic Drugs
|